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Abstract
Leukoplakia is the most common potentially malignant disorder of the oral mucosa. The prevalence is approxi-
mately 1% while the annual malignant transformation ranges from 2% to 3%. At present, there are no reliable 
clinicopathological or molecular predicting factors of malignant transformation that can be used  in an individual 
patient and such event can not truly be prevented. Furthermore, follow-up programs are of questionable value in 
this respect. Cessation of smoking habits may result in regression or even disappearance of the leukoplakia and 
will diminish the risk of cancer development either at the site of the leukoplakia or elsewhere in the mouth or the 
upper aerodigestive tract.
The debate on the allegedly potentially malignant character of oral lichen planus is going on already for several 
decades. At present, there is a tendency to accept its potentially malignant behaviour, the annual malignant trans-
formation rate amounting less than 0.5%. As in leukoplakia, there are no reliable predicting factors of malignant 
transformation that can be used in an individual patient and such event can not truly be prevented either. Follow-up 
visits, e.g twice a year, may be of some value.
It is probably beyond the scope of most dentists to manage patients with these lesions in their own office. Timely 
referral to a specialist seems most appropriate, indeed.
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Introduction
At present, preference is given in the literature to the 
use of the adjective “potentially malignant” rather than 
to premalignant or precancerous. Furthermore, in case 
of leukoplakia one favors to use “disorder” instead of 
lesion as was done in the past, recognizing the fact that 
malignant transformation does not always take place in 
the leukoplakic area, but also elsewhere in the mouth or 
even elsewhere in the upper aerodigestive tract.
The following disorders are regarded as being potential-
ly malignant: 1) leukoplakia/erythroplakia, 2) submu-
cous fibrosis, 3) palatal lesions in reverse smokers, and, 
although still somewhat questionable 4) lichen planus, 
and 5) discoid lupus erythematosus. In addition, in  pa-
tients suffering from rare, inherited syndromes such as 
xeroderma pigmentosum and Fanconi’s anemia, there 
is an increased incidence of oral cancer. This is also the 
case in immunodefiency, e.g. due to the prolonged use 
of immunosuppressive drugs or due to an underlying 
HIV-infection. Oral cancer has also been reported in 
patients suffering from chronic Graft Versus Host Dis-
ease after stem cell transplantation.
In this paper, the emphasis will be on leukoplakia/eryth-
roplakia and lichen planus. In several recent reports in 
the literature the subject of  leukoplakia and lichen pla-
nus has been combined under the heading of potentially 
malignant disorders, not clearly making a distinction 
between these two entities. In the present report, these 
two entities will be delt with separately.
1. Leukoplakia and erythroplakia
In the past decades little progress has been made in 
defining oral leukoplakia. In 1978, the World Health 
Organisation defined leukoplakia as “a white patch or 
plaque that cannot be characterized clinically or patho-
logically as any other disease” (1). In that communica-
tion it was noted, that the term leukoplakia was unre-
lated to the absence or presence of epithelial dysplasia. 
In 2005, the World Health Organisation defined leuko-
plakia as “a white plaque of questionable risk having 
excluded (other) known diseases or disorders that carry 
no increased risk for cancer” (2). Both the 1978 and the 
2005 definition are worded in a somewhat negative way. 
Besides, when accepting the view that lichen planus is 
a potentially malignant disorder (to be discussed later), 
then this disease actually falls within the 2005 WHO 
definition of leukoplakia.
The prevalence of leukoplakia for all ages is approxi-
mately one per cent, with an increasing prevalence in 
adults. The male-female ratio varies in different parts of 
the world. Smoking is the most common etiologic fac-
tor. Nevertheless, leukoplakia may occur in non-smok-
ers as well. Cessation of smoking habits may result in 
regression or even disappearance of the leukoplakia in a 
matter of a few months.
When the incidence of oral cancer is set at 5 per 100.000 
population per year, then an annual risk of malignant 
transformation in oral leukoplakia patients of 2% is a 
four hundred times increased risk. Apparently, this fig-
ure qualifies for a “significantly” increased risk.
Prevalence figures of erythroplakia are only available 
from studies in South- and South East Asia and are as 
low as 0.02% (3). The annual malignant transformation 
rate is actually unknown but is much higher than in leu-
koplakia. Because of its rarity, this entity will not be 
discussed here any further. 
1.1- Risk factors of malignant transformation in leuko-
plakia 
In general, it seems well accepted that the annual ma-
lignant transformation rate of leukoplakia amounts 
2%-3% for all clinical subtypes together, including the 
ill-defined and much debated entity of proliferative ver-
rucous leukoplakia. 
There are numerous reported parameters that alleg-
edly predict future malignant transformation of oral 
leukoplakia. These parameters include previously diag-
nosed cancer in the head and neck region, older age, 
female gender, absence of smoking habits, duration of 
the leukoplakia, clinical subtype (homogeneous versus 
non-homogeneous), large seize, and oral subsite such as 
borders of the tongue and floor of the mouth (4). The use 
of toluidine blue staining may help to identify high-risk 
leukoplakias with poor outcome (5). Other predicting 
factors include the presence of C. albicans, the presence 
and severity of epithelial dysplasia, and, in addition, nu-
merous molecular markers, such as aberrant expression 
of p16INK4a and Ki-67, (6) chromosome instability, (7) 
and loss of heterozygosity at 9p and mutated TP53 (8).
Some of the predicting factors mentioned above carry a 
certain degree of subjectivity. For instance, it may diffi-
cult to objectively define the clinical homogeneous sub-
type. Some clinicians use this adjective only in case of 
thin , smooth and homogeneously white lesions, while 
others may apply this adjective also in homogeneously 
white and homogeneously verrucous lesions. The his-
topathological assesment of the presence of epithelial 
dysplasia and the degree of dysplasia is another source 
of substantial subjectivity.
At present, there is no single marker or set of markers 
that reliably can be used to predict malignant trans-
formation of oral leukoplakia in an individual patient. 
Statistically, when applied to a large group of patients, 
non-homogeneous clinical subtype, large seize, pres-
ence of epithelial dysplasia and location on the tongue 
or the floor of the mouth (at least in the Western world; 
in India the buccal mucosa is the most common oral 
subsite at risk) seem to be the most relevant predictors 
of malignant transformation (Fig. 1).
1.2- Treatment and follow-up
The main treatment modalities for oral leukoplakia can 
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be divided in surgical treatment, including lasers, and 
non-surgical treatment.
While in oncologic surgery a margin of 1 cm beyond the 
visible or palpable extent of the oral cancer  is a widely 
accepted guideline, no such guideline is available for 
the treatment of leukoplakia. Besides, in many leuko-
plakias there is no sharp delineation, thereby  hinder-
ing to extent the excision or laser evaporation well into 
normal appearing mucosa.
Local recurrences after surgical treatment, including 
lasers, are not uncommon (Figs. 2,3), the annual recur-
rence rate being approximately 5%-10% (9,10). In spite 
of an occasional retrospective study suggesting the op-
posite, (11) surgical treatment of leukoplakia does not 
seem to reduce the risk of future development of oral 
cancer either at the site of the leukoplakia or at another 
site in the oral cavity or the upper aerodigestive tract. 
Such observation has been made in several recent stud-
ies, e.g. by Arduino et al. (12) and  Brouns et al. (13) but 
also in studies performed in the sixties of the past cen-
tury. (14) The same applies to the result of non-surgical 
treatment (15,16).
There is no evidence that lifelong follow-up programs in 
treated or untreated patients with leukoplakia are effec-
tive in preventing the development of oral cancer. Most 
likely, follow-programs will not result in improved sur-
vival in case of cancer development either.
Cessation of smoking habits considerably reduces the 
risk of developing cancer after surgical treatment of oral 
potentially malignant lesions (17).
1.3- Patients’ management
Although removal of leukoplakia most likely will not 
eliminate or even reduce the risk of future development 
of oral cancer, most patients probably will prefer to have 
the leukoplakiaa removed, if feasible, when balanced 
against the morbidity of the treatment. In case of oral 
cancer development in a solitary, small (2cm-3cm) and 
Fig. 1. Homogeneous leukoplakia in a 57-year-old man A). A biopsy 
showed hyperkeratosis without epithelial dysplasia. The patient was 
unable to stop smoking and refused any type of treatment. He was 
lost to follow-up and showed up 12 years later with a large squamous 
cell carcinoma B).
Fig. 2. A 61-year-old woman with homogeneous leukoplakia in the 
floor of the mouth A). A biopsy showed hyperkeratosis without epi-
thelial dysplasia. Treatment consisted of CO2 laser evaporation, re-
sulting in an apparently good result after 6 months B). Six years later 
the leukoplakia had recurred C).
A
B
C
A
B
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well-circumscribed leukoplakia, the patient will, con-
ceivably, regret the decision of non-treatment in such 
instance. Also the clinician will probably feel “guilty” 
of not having recommended treatment in such cases.
In case of non-treatment, most patients prefer to be fol-
lowed-up, in spite of the questionable efficacy of such 
follow-up. Depending on various aspects, such as the 
extent of the leukoplakia and the presence and degree 
of epithelial dysplasia, intervals may vary from 3-6 
months, lifelong. Changes in the clinical manifestation 
and, particularly, symptoms are ominous signs of ma-
lignant transformation.
It is probably beyond the scope of most dentists to man-
age patients with oral leukoplakia in their own office. 
Instead, timely referral to a specialist seems most ap-
propriate.
2. Oral lichen planus
The prevalence of oral lichen planus is in general accept-
ed to be approximately 1 per cent. This chronic disorder 
mainly affects middle-aged people. The etiopathogenesis 
is still poorly understood. There is no effective treatment 
and there are no preventive measures either.
The debate on the allegedly potentially malignant char-
acter of oral lichen planus is going on already for several 
decades (18-23). In a seven-year follow-up study of 327 
patients the annual maligant transformation rate amount-
ed less than 0.5% (24). When the incidence of oral cancer 
is set at 5 per 100.000 per year, then an annual risk of 
malignant transformation in oral lichen planus patients of 
0.5% is a hundred times increased risk. Is this sufficient 
for qualification as a “significantly increased risk”? The 
cancer may develop anywhere in the oral cavity, not nec-
essarily at the site of the lichen planus.
An important obstacle in the discussion on the possible 
potentially malignant character of oral lichen planus is 
caused by the lack of clear clinical and histopathologic 
diagnostic criteria of oral lichen planus, resulting in a 
poor clinicopathologic correlation in the diagnosis (25). 
In daily practice it is, indeed,  sometimes impossible to 
reliably make a distinction between the various clini-
cal manifestations of lichen planus and those of  leu-
koplakia, both clinically and histopathologically. An-
other area of confusion is the recognition of so-called 
lichenoid lesions, e.g. amalgam related lesions.
2.1- Risk factors of malignant transformation in lichen 
planus
There are no known clinical or histopathologic features 
in oral lichen planus that predict possible maligant trans-
fromation. In general, the presence of epithelial dyspla-
sia is not accepted within the diagnostic spectrum of 
oral lichen planus. In this respect, the term “lichenoid 
dysplasia” is a rather confusing one (26). There are only 
a few studies on molecular markers that might be of pre-
dicting value with regard to malignant transformation 
in oral lichen planus (27-29). At present, no such mark-
ers have shown to be of strong predictive power.
2.2-  Follow-up programs
The efficacy of continous, lifelong follow-up of patients 
with oral lichen planus is questionable, (30) although 
structured follow-up visits  have been suggested to be 
beneficial in some studies (31).
2.3-  Patients’ management
In daily practice it may be difficult to manage patients 
with oral lichen planus with regard to the debatable 
issue of premalignancy, even when the annual malig-
nant transformation is set at a percentage of less than 
0.5 per cent. There is no effective treatment for lichen 
planus, there are no known predictive factors of malig-
nant transformation, it is not possible to prevent future 
cancer development and the efficacy of follow-up is at 
least questionable. The general advice in these circum-
stances is to perform an oral examination at least once a 
year, preferably twice a year. These examinations could 
be performed by dentists in their own office without the 
need for routine referral to a specialist.
Conclusion
At present, there are no reliable predicting factors of 
malignant transformation that can be used  in an in-
dividual patient with oral leukoplakia and such event 
Fig. 3. A 63-year-old man with verrucous leukoplakia of the buc-
cal mucosa A). The leukoplakia recurred within three weeks after 
surgical removal B).
A
B
Med Oral Patol Oral Cir Bucal. 2014 Jul 1;19 (4):e386-90.                                                                                                                                                              Oral potentially malignant disorders
e390
can not truly be prevented. Furthermore, follow-up pro-
grams are of questionable value.
At present, there is a tendency to accept that oral li-
chen planus is a potentially malignant disorder, the an-
nual malignant transformation rate amounting less than 
0.5%. As in leukoplakia, there are no reliable predicting 
factors of malignant transformation that can be used in 
an individual patient and such event can not truly be 
prevented either. Follow-up visits, e.g twice a year, may 
be of some value.
It is a challenge for the dentists to convey the views on 
oral potentially malignant disorders to their patients. Some 
patients will be able to draw their own conclusions and to 
properly balance the aspects of the morbity of treatment 
and the questionable benefit of such treatment. Others may 
not be able to oversee the various aspects of potentially 
malignant disorders and the lack of prediction and preven-
tion of malignant transformation. In case of leukoplakias 
that are localized and well-circumscribed removal seems 
advisable in such instances. In any event, follow-up is rec-
ommended in spite of its questionable value.
In case of lichen planus follow-up at 6-12 months, life-
long, seems a reasonable advise.
Particularly in case of oral leukoplakia most dentists 
will probably feel the need to refer the patient to a spe-
cialist for diagnostic reasons and, even more so, for de-
termining the management policy. 
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